Firefly Neuroscience Unveils AI-Powered Brain Age Biomarker Using FDA-Cleared BNA™ Platform

Curated by THEOUTPOST

On Wed, 15 Jan, 12:03 AM UTC

2 Sources

Share

Firefly Neuroscience announces a breakthrough in assessing cognitive brain age using its FDA-cleared BNA™ technology, potentially revolutionizing early detection and monitoring of neurological disorders like Alzheimer's.

Breakthrough in Brain Age Assessment

Firefly Neuroscience, Inc. (NASDAQ: AIFF), an AI-driven healthcare company, has announced a significant advancement in brain health research. The company has developed a method to assess a patient's cognitive brain age using its FDA-cleared Brain Network Analytics (BNA™) technology platform 1.

Innovative Use of EEG Data

Gil Issachar, Chief Technology Officer of Firefly, presented the groundbreaking findings at AD/PD 2024. The BNA™ system utilizes both Resting EEG and Cognitive EEG (ERP) data to estimate the biological age of a person's brain. This marks the first instance where cognitive data measured by ERP has been successfully used for assessing biological brain age 1.

Potential Impact on Dementia and Alzheimer's Detection

The technology has shown promise in identifying disparities between brain age and chronological age, which could serve as a valuable risk factor for dementia. By enabling the measurement of brain age through EEG, Firefly is potentially opening doors to a proactive and scalable approach for early screening and monitoring of Alzheimer's patients 1.

AI-Powered Brain Health Solutions

Firefly's BNA™ technology was developed using artificial intelligence and machine learning, leveraging a comprehensive database of over 17,000 patients representing twelve disorders and clinically normal patients. The system, when used in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function, enhancing their ability to accurately diagnose mental and cognitive disorders and evaluate optimal therapies 1.

Market Response and Future Prospects

The announcement of this breakthrough has had a significant impact on Firefly Neuroscience's market performance. The company's shares doubled to $3.90 following the news, reflecting investor confidence in the potential of the BNA™ platform 2.

Commercialization and Industry Impact

Firefly is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use. This move could potentially revolutionize diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD 1.

Continue Reading
Firefly Neuroscience's AI-Powered EEG Analytics Show

Firefly Neuroscience's AI-Powered EEG Analytics Show Promise in Drug Development and Neuropsychiatric Care

Firefly Neuroscience's FDA-cleared BNA™ platform, utilizing AI and machine learning, demonstrates significant potential in providing objective measures for drug efficacy and cognitive changes in neuropharmacology and psychiatry.

Investing.com UK logoBenzinga logo

2 Sources

Investing.com UK logoBenzinga logo

2 Sources

Firefly Neuroscience Secures $12.4 Million Financing to

Firefly Neuroscience Secures $12.4 Million Financing to Advance AI-Powered Brain Health Technology

Firefly Neuroscience, an AI company focused on brain health solutions, has closed a financing deal of up to $12.4 million to support the commercialization of its FDA-cleared Brain Network Analytics technology.

Investing.com UK logoBenzinga logo

2 Sources

Investing.com UK logoBenzinga logo

2 Sources

Firefly Neuroscience Stock Soars After Joining NVIDIA

Firefly Neuroscience Stock Soars After Joining NVIDIA Connect Program for Brain Modeling Initiative

Firefly Neuroscience's stock surges over 200% following its acceptance into NVIDIA's Connect program, aiming to develop an AI-powered foundation model of the human brain using its FDA-cleared Brain Network Analytics technology.

Benzinga logoDataconomy logo

3 Sources

Benzinga logoDataconomy logo

3 Sources

Firefly Neuroscience Grants Inducement Shares to Executive

Firefly Neuroscience Grants Inducement Shares to Executive Chairman, Highlighting AI-Driven Brain Health Solutions

Firefly Neuroscience, an AI company focused on brain health, announces an inducement grant to its Executive Chairman and discusses its innovative Brain Network Analytics technology.

Benzinga logoInvesting.com UK logo

2 Sources

Benzinga logoInvesting.com UK logo

2 Sources

Firefly Neuroscience to Showcase AI-Powered Brain Health

Firefly Neuroscience to Showcase AI-Powered Brain Health Solutions at October Investor Conferences

Firefly Neuroscience, an AI company specializing in brain health diagnostics, announces its participation in two major investor conferences in October 2024, highlighting its innovative Brain Network Analytics technology.

Investing.com UK logoBenzinga logo

2 Sources

Investing.com UK logoBenzinga logo

2 Sources

TheOutpost.ai

Your one-stop AI hub

The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.

© 2025 TheOutpost.AI All rights reserved